Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Baxter burn treatment gains FDA go-ahead: Baxter plans to launch its Artiss fibrin sealant adhesive for attaching skin grafts onto burn patients at the American Burn Association annual meeting April 29-May 2 in Chicago after receiving biologic license application approval March 19. Artiss is the "first and only" slow-setting fibrin sealant approved for the indication, Baxter notes. Unlike rapid-setting fibrin sealant tissue adhesives, which also contain the blood-clotting proteins fibrinogen and thrombin, Artiss has a lower concentration of thrombin, FDA notes. This allows surgeons more time to position the grafts before adherence to the skin, according to the agency. Intended as an alternative to staples, Artiss also contains aprotinin, a synthetic protein that delays the breakdown of blood clots
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel